HC Wainwright Issues Negative Forecast for MOLN Earnings

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) – Investment analysts at HC Wainwright reduced their Q2 2026 EPS estimates for Molecular Partners in a research report issued to clients and investors on Monday, July 6th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.45) for the quarter, down from their prior forecast of ($0.44). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Molecular Partners’ Q4 2026 earnings at ($0.46) EPS, FY2026 earnings at ($1.81) EPS, Q1 2027 earnings at ($0.47) EPS, Q2 2027 earnings at ($0.42) EPS, Q3 2027 earnings at ($0.38) EPS, Q4 2027 earnings at ($0.38) EPS and FY2027 earnings at ($1.65) EPS.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02).

Several other brokerages have also commented on MOLN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research report on Friday, April 10th. TD Cowen reaffirmed a “buy” rating on shares of Molecular Partners in a research note on Monday, March 16th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $8.38.

Molecular Partners Stock Up 2.2%

Shares of MOLN stock opened at $4.09 on Wednesday. The business has a 50-day moving average price of $3.99 and a two-hundred day moving average price of $4.27. Molecular Partners has a 12-month low of $3.41 and a 12-month high of $5.36. The firm has a market cap of $165.15 million, a P/E ratio of -2.11 and a beta of 1.08.

Institutional Trading of Molecular Partners

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new position in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 12,311 shares of the company’s stock, valued at approximately $54,000. Hedge funds and other institutional investors own 26.55% of the company’s stock.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.